16758 results for "sec+and+unspecified+malignant+neoplasm"

in 170.42 milliseconds.

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A95670B

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 636 samples; filetype=bam

  Dataset EGAD00001004754

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A95724A

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 480 samples; filetype=bam

  Dataset EGAD00001004756

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A95732B

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 635 samples

  Dataset EGAD00001004760

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96139A

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1436 samples; filetype=bam

  Dataset EGAD00001004762

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96150A

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 656 samples; filetype=bam

  Dataset EGAD00001004764

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96156B

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 375 samples; filetype=bam

  Dataset EGAD00001004766

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96171A

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 492 samples; filetype=bam

  Dataset EGAD00001004768

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library A96187A

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 1222 samples; filetype=bam

  Dataset EGAD00001004770

• STREP GENE: Genetics and Severe Streptococcal Infections

  This study investigated host genetic susceptibility to invasive group A streptococcal disease in the UK. Cases were either survivors recruited retrospectively through a patient group or identified from the a tissue bank at Imperial College London. Those recruited through the patient group had survived an episode of invasive GAS disease at a UK hospital since 1980 with microbiological confirmation obtained either through Public Health England or from the treating hospital. Those identified from the tissue bank had been diagnosed with invasive GAS disease at the Hammersmith Hospital, London, UK, since 2006. All cases aged less than 65 years without long-term medical conditions genome-wide genotyped using either the Illumina HumanCore or the Global Screening Array platform.

  Study EGAS00001003421

• Whole exome sequencing of a representative cohort of AML

  The Genomic DNA Clean & Concentrator kit (ZYMO Research) was used to remove EDTA from the DNA samples. Sample libraries were prepared using 100 ng of input according to the KAPA HyperPlus Kit (Roche) using Unique Dual Index adapters (Integrated DNA Technologies, Inc.). Exomes were captured using the SeqCap EZ MedExome (Roche Nimblegen) according to SeqCap EZ HyperCap Library v1.0 Guide (Roche) with the xGen Universal blockers – TS Mix (Integrated DNA Technologies, Inc.). The amplified captured sample libraries were paired-end sequenced (2x100 bp) on the Novaseq 6000 platform (Illumina) and aligned to the hg19 reference genome using the Burrows-Wheeler Aligner (BWA)3, v0.7.15-r1140.

  Dataset EGAD00001007580

• Whole-exome sequencing of hepatocellular carcinoma biopsies

  All 122 HCC biopsies and 115 non-tumoral tissues from 114 patients were subjected to whole-exome sequencing. Whole-exome capture was performed using the SureSelectXT Clinical Research Exome (Agilent Technologies) or SureSelect Human All Exon V6+COSMIC (Agilent Technologies) platforms according to the manufacturer’s guidelines. Sequencing was performed on an Illumina HiSeq 2500 at the Genomics Facility Basel according to the manufacturer’s guidelines. Paired-end 101-bp reads were generated.

  Dataset EGAD00001008182

• Whole genome sequencing OMElib

  The mutational landscape of haematopoietic cells will be characterized by WGS following amplification of DNA and preparation of libraries by PTA(primary template-directed amplification). Samples have been sourced from the Cambridge Biobank.

  Dataset EGAD00001015251

• RNA Seq OMELib

  The transcriptional landscape of haematopoietic cells will be characterized by RNA Seq following amplification of RNA/cDNA and preparation of libraries by PTA(primary template-directed amplification). Samples have been sourced from the Cambridge Biobank.

  Dataset EGAD00001015252

• HELIUS cohort gut microbiome

  The gut microbiota composition is unique to every individual but is shaped by common factors including diet, lifestyle, medication use, early-life determinants, living environment or genetics. Most of these factors may be influenced by ethnicity. This study explored variations in fecal microbiota composition in 6048 individuals with different ethnic backgrounds living in the same geographical area (Amsterdam, the Netherlands). The HELIUS data are owned by the Amsterdam University Medical Centers, location AMC in Amsterdam, The Netherlands. To allow sharing of microbiome data collected in HELIUS with (inter)national researchers, 16s rRNA sequence analysis has been stored at the European genome-phenome archive (EGA; accession code EGAD00001004106). This requires that access needs to be granted, also because the HELIUS data are stored with relevant phenotypical variables. Access is granted to all researchers affiliated with an internationally recognized research institution who request to use the HELIUS data within the EGA context, after having signed the data transfer agreement. Any researcher can request the data by submitting a proposal to the HELIUS Executive Board as outlined at http://www.heliusstudy.nl/en/researchers/collaboration, by email: heliuscoordinator at amsterdamumc dot nl. The HELIUS Executive Board will check proposals if they do not conflict with ethical approvals and informed consent forms of the HELIUS study.

  Dataset EGAD00001004106

• Exome sequencing of Congenital Heart Disease families Toronto

  The exome sequencing is performed using Agilent SureSelect 50Mb exome v3 and Hiseq 75bp paired reads with an mean sequencing coverage target of 50X.

  Dataset EGAD00001000799

• Whole genome sequencing of single cells identifies stochastic aneuploidies, genome replication, states, and clonal repertoires for library for library A95728A

  Transposase-based amplification-free single-cell genome direct library preparation in nanowell chips; 844 samples; filetype=bam

  Dataset EGAD00001004758

• HELIUS cohort gut microbiome batch2

  The gut microbiota composition is unique to every individual but is shaped by common factors including diet, lifestyle, medication use, early-life determinants, living environment or genetics. Most of these factors may be influenced by ethnicity. This study explored variations in fecal microbiota composition in 6048 individuals with different ethnic backgrounds living in the same geographical area (Amsterdam, the Netherlands). The HELIUS data are owned by the Amsterdam University Medical Centers, location AMC in Amsterdam, The Netherlands. To allow sharing of microbiome data collected in HELIUS with (inter)national researchers, 16s rRNA sequence analysis has been stored at the European genome-phenome archive (EGA; accession code EGAD00001004106). This requires that access needs to be granted, also because the HELIUS data are stored with relevant phenotypical variables. Access is granted to all researchers affiliated with an internationally recognized research institution who request to use the HELIUS data within the EGA context, after having signed the data transfer agreement. Any researcher can request the data by submitting a proposal to the HELIUS Executive Board as outlined at http://www.heliusstudy.nl/en/researchers/collaboration, by email: heliuscoordinator at amsterdamumc dot nl. The HELIUS Executive Board will check proposals if they do not conflict with ethical approvals and informed consent forms of the HELIUS study.

  Dataset EGAD00001009732

• The mutation burden of narrowband ultraviolet B phototherapy in human skin - Nanoseq

  Background: Ultraviolet radiation (UV) is used as a treatment for psoriasis, but UV can also induce mutations which may lead to development of skin cancer. Information on the mutagenicity of narrowband UVB (NBUVB) would help inform clinicians and patients who are concerned about the potential risks of this treatment.

  Dataset EGAD00001015249

• The mutation burden of narrowband ultraviolet B phototherapy in human skin - WGS

  Background: Ultraviolet radiation (UV) is used as a treatment for psoriasis, but UV can also induce mutations which may lead to development of skin cancer. Information on the mutagenicity of narrowband UVB (NBUVB) would help inform clinicians and patients who are concerned about the potential risks of this treatment.

  Dataset EGAD00001015250

• Validation of AML Mutational Screening

  We recently worked-up a pulldown protocol for studying 21 genes recurrently mutated in AML (Study1770). Our manuscript is currently under revision and to address the reviewers' comments we need to validate some mutations by re-sequencing. In this add-on study we will be using PCR followed by MiSeq for this purpose.

  Dataset EGAD00001000445

• Tumor-associated preferred end coordinates and somatic variants as signatures of circulating tumor DNA

  Cell-free DNA fragmentation is a nonrandom process. We showed that cell-free DNA fragments with ends at certain genomic coordinates had higher likelihoods of being derived from hepatocellular carcinoma. Other coordinates were associated with cell-free DNA molecules originating from the liver. Quantitative assessment of cell-free DNA molecules bearing these respective groups of end signatures correlated with the amounts of tumor-derived or liver-derived DNA in plasma. There were millions of tumor-associated plasma DNA end coordinates across the genome. Due to their high prevalence, they were more readily detectable than somatic mutations as a cancer signature in plasma. Hence, detection of tumor-associated plasma DNA ends may offer a cost-effective means of capturing evidence for the presence of cancer through liquid biopsy assessment.

  Study EGAS00001003160

• WGS of OvCa

  WGS data relative to 63 primary and treatment-naive ovarian carcinomas, from independent donors.

  Dataset EGAD00001008581

• Whole Exome sequencing of colorectal cancer patients (SG-BULK)

  DNA-seq libraries were captured to exome regions using xGen Exome Research Panel v1.0 (IDT), and libraries were prepared using the KAPA Hyper prep kit. DNA libraries were sequenced to a target depth of ×200 for tumor sample, ×100 for normal samples on the Illumina HiSeq platform.

  Dataset EGAD00001008543

• RNA-seq data from 224 advanced prostate tumors generated by the West Coast Dream Team

  224 pairs of FASTQ files from metastatic Castration-Resistant Prostate Cancer (mCRPC) sequenced on HiSeq 4000 instruments. Patients were enrolled in the West Coast Dream Team study. Biopsies include various tissue sites including bone, soft tissue, and lymph node.

  Dataset EGAD00001008487

• De novo mutations in cell-free foetal DNA (cffDNA)

  This project is to develop and validate a method to detect de novo mutations in a foetal genome through deep sequencing of cell-free DNA from the plasma of pregnant women. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

  Dataset EGAD00001000596

• Deep sequencing analysis of human iPSC-specific SNVs in donor cell population

  CR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation. The library will be sequenced either by HiSeq or MiSeq. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

  Dataset EGAD00001000605

• Deep sequencing of S7EPC genome

  PCR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation. The library will be sequenced either by HiSeq or MiSeq. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

  Dataset EGAD00001000607

• UK10K_COHORT_ALSPAC REL-2012-06-02

  UK10K_COHORT_ALSPAC REL-2012-06-02: Low-coverage whole genome sequencing; variant calling, genotype calling and phasing

  Dataset EGAD00001000740

• UK10K_COHORT_TWINSUK REL-2012-06-02

  UK10K_COHORT_TWINSUK REL-2012-06-02: Low-coverage whole genome sequencing; variant calling, genotype calling and phasing

  Dataset EGAD00001000741

• Sequencing of pancreatic cancer primary tumors and metastases

  The extent of heterogeneity of driver gene mutations present in naturally occurring metastases is largely unknown, i.e. treatment-naïve metastatic disease. To address this issue, 60x whole genome sequencing of 26 metastases from 4 patients was carried out. We found that the identical driver gene mutations were present in every metastatic lesion of each patient studied. Passenger gene mutations not known or predicted to have functional consequences accounted for all intratumoral heterogeneity. Even with respect to these passenger gene mutations, the genetic similarity among the founding cells of metastases was markedly higher than that expected for any two cells randomly taken from a normal tissue. The uniformity of driver gene mutations among metastases in the same patient has critical, encouraging implications for the success of future targeted therapies in advanced stage disease.

  Study EGAS00001002186

• Whole genome landscape of adult T-cell leukemia/lymphoma

  Whole-genome sequence (WGS) data of tumor-normal pairs from 139 ATL patients and RNA sequence (RNA-seq) data of tumors from 28 ATL patients.

  Dataset EGAD00001008289

• sWGS of core biopsies from localized breast cancer patients

  Paired end shallow whole genome sequencing (sWGS) data for the identification of genomewide somatic copy number alterations (SCNA) and the estimation of tumor fractions.

  Dataset EGAD00001008397

• WXS and RNA-seq raw sequence data for TG project

  WXS sequence data from 112 samples, RNA-seq sequence data from 117 samples, all sequence data are raw sequence data in fastq format, sequenced by Illumina platform.

  Dataset EGAD00001007989

• Ancient Yakuts genomes and metagenomes

  Read data and bam alignments for 124 ancient yakuts

  Dataset EGAD50000001903

• Assessment of genetic and epigenetic variation in human IPS cells

  In order to progress human induced pluripotent stem cells (hiPSCs) towards the clinic, several outstanding questions must be addressed. It is possible to reprogram different somatic cell types into hiPSCs but it is unclear whether some cell types carry through fewer mutations through reprogramming (either due to mutations present in the primary cells, or mutations accumulated during reprogramming). Through in depth analysis of hiPSCs generated from different somatic cells, it will be possible to assess the variation in genetic stability of different cell types.

  Dataset EGAD00001000798

• Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

  Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors in 43 patients with untreated TNBC. The primary endpoint, decreased Ki67, occurs in 12% of TNBC. Multiple different approaches identify HR deficiency in the majority of TNBC, 69% with the mutational-signature-based HRDetect assay. Cancers with mutational signatures of HR deficiency have a functional defect in HR. Following rucaparib treatment there is no association of Ki67 change with HR deficiency. In contrast, early circulating tumor DNA dynamics identify activity of rucaparib in cancers with mutation-signatures of HR deficiency, with rucaparib inducing expression of interferon response genes in HR deficient cancers. The majority of TNBCs have a defect in DNA repair, identifiable by mutational signature analysis, that may be targetable with PARP inhibitors.

  Study EGAS00001004405

• ANGIOPREDICT - an FP7-funded project enabling personalised medicine for patients with metastatic colorectal cancer.

  Exome (*_{N,T}{1,2}) RNAseq (polyA - *_PolyA, and RiboZero - *_RibZ) Methylation (SeqCapEpi - MAPD*).

  Dataset EGAD00001008463

• Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer

  Dataset EGAD00001007858

• Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas

  Bulk RNA-seq data of tumour data.

  Dataset EGAD00001006794

• Validation of a Haloplex platform for targeted re-sequencing of the exons of 25 genes

  We recently used the Agilent SureSelect platform to re-sequence a set of genes known to be mutated in human AML. The results from 10 AML DNA samples were very satisfactory, but the effort required was significant. Thus, we decided to re-sequence the same genes using the Haloplax system for target enrichment in 48 AML samples. We planned to do this using MiSeq and have data from a pilot of 3 samples. The data is promising but coverage appears pathcy so far. However, in order to get a better understanding of the data we will need deeper sequencing. We will need two lanes of HiSeq to get the same degree coverage as Sureselect. his data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

  Dataset EGAD00001000603

• NPC genome-wide human SNP array data

  nasopharyngeal carcinoma genome-wide human SNP array data for 4083 NPC cases and 4811 controls

  Dataset EGAD00010002296

• The Dutch Microbiome Project Batch 2

  The Dutch Microbiome Project (DMP) data includes shotgun metagenomic sequencing of faecal samples 8,208 Dutch individuals. Paired-end sequencing was performed using Illumina HiSeq 2000 platform. Data is archived in two batches to facilitate easier data access and upload to EGA. Batch 2 of DMP includes ~400 samples.

  Dataset EGAD00001007501

• EPICC: Evolutionary Predictions in Colorectal Cancer

  ATAC-seq profiling bam files from colorectal carcinoma and adenoma.

  Dataset EGAD00001008140

• Covid19 WGS variants analysis

  483 samples were collected for WGS and aligned with GRCh38 human genome. The variants were called using GATK (Sentieon v. 201808.03) in GVCF and VCF format.

  Dataset EGAD00001010138

• Gut metagenome from Estonian Microbiome Cohort

  Stool samples were collected from 2,509 Estonian Biobank participants. The shotgun metagenomic paired-end sequencing was performed by Novogene Bioinformatics Technology Co., Ltd. using the Illumina NovaSeq6000 platform, resulting in 4.62 ± 0.44 Gb of data per sample (insert size, 350 bp; read length, 2 × 250 bp). A total of 2,513 samples belonging to 2,509 individuals were sequenced, including 4 biological replicates from one individual. First, the reads were trimmed for quality and adapter sequences. The host reads that aligned to the human genome were removed using SOAP2.21 (parameters: -s 135 -l 30 -v 7 -m 200 -x 400).

  Dataset EGAD00001008448

• RNAseq data for Failure of Differentiation of the Rhombic Lip Constitutes Medulloblastoma

  We used single-cell transcriptomics to study cells from the developing human cerebellum, and show that different molecular subgroups of medulloblastoma resemble distinct glutamatergic progenitors.

  Dataset EGAD00001008458

• Irish Covid19 WGS Alignment Data

  Dataset contains 483 Irish origin Individuals with Covid19. For WGS, Alignment has been done using BWA-mem (sention v 201808.03 ) and BAM file generated.

  Dataset EGAD00001010098

• Next Generation Children project

  Whole genome sequencing of sick children in neonatal and paediatric intensive care units, aligned to reference assembly GRCh38.

  Dataset EGAD00001007868

• EPICC: Evolutionary Predictions in Colorectal Cancer WGS-3

  WGS profiling bam files from colorectal carcinoma and adenoma.

  Dataset EGAD00001008642

• Cellular indexing of transcriptomes and epitopes sequencing of peritoneal fluid from patients with achalasia

  The data published here contains cellular indexing of transcriptomes and epitopes sequencing (CITEseq) using the oligo-tagged TotalSeq™-B Human Universal Cocktail, V1.0 from BioLegend on peritoneal fluid (PF) from patients with achalasia. Sequencing was performed in a paired-ended fashion on the NovaSeq6000. Below an overview of the epitopes to oligotags as obtained from BioLegend: DNA_ID Description clone Sequence Ensembl ID B0006 anti-human CD86 IT2.2 GTCTTTGTCAGTGCA ENSG00000114013 B0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 GTTGTCCGACAATAC ENSG00000120217 B0020 anti-human CD270 (HVEM, TR2) 122 TGATAGAAACAGACC ENSG00000157873 B0023 anti-human CD155 (PVR) SKII.4 ATCACATCGTTGCCA ENSG00000073008 B0024 anti-human CD112 (Nectin-2) TX31 AACCTTCCGTCTAAG ENSG00000130202 B0026 anti-human CD47 CC2C6 GCATTCTGTCACCTA ENSG00000196776 B0029 anti-human CD48 BJ40 CTACGACGTAGAAGA ENSG00000117091 B0031 anti-human CD40 5C3 CTCAGATGGAGTATG ENSG00000101017 B0032 anti-human CD154 24-31 GCTAGATAGATGCAA ENSG00000102245 B0033 anti-human CD52 HI186 CTTTGTACGAGCAAA ENSG00000169442 B0034 anti-human CD3 UCHT1 CTCATTGTAACTCCT ENSG00000167286 B0046 anti-human CD8 SK1 GCGCAACTTGATGAT ENSG00000153563 B0047 anti-human CD56 (NCAM) 5.1H11 TCCTTTCCTGATAGG ENSG00000149294 B0050 anti-human CD19 HIB19 CTGGGCAATTACTCG ENSG00000177455 B0052 anti-human CD33 P67.6 TAACTCAGGGCCTAT ENSG00000105383 B0053 anti-human CD11c S-HCL-3 TACGCCTATAACTTG ENSG00000140678 B0058 anti-human HLA-A,B,C W6/32 TATGCGAGGCTTATC ENSG00000206503 B0063 anti-human CD45RA HI100 TCAATCCTTCCGCTT ENSG00000081237 B0064 anti-human CD123 6H6 CTTCACTCTGTCAGG ENSG00000185291 B0066 anti-human CD7 CD7-6B7 TGGATTCCCGGACTT ENSG00000173762 B0068 anti-human CD105 43A3 ATCGTCGAGAGCTAG ENSG00000106991 B0070 anti-human/mouse CD49f GoH3 TTCCGAGGATGATCT ENSG00000091409 B0071 anti-human CD194 (CCR4) L291H4 AGCTTACCTGCACGA ENSG00000183813 B0072 anti-human CD4 RPA-T4 TGTTCCCGCTCAACT ENSG00000010610 B0073 anti-mouse/human CD44 IM7 TGGCTTCAGGTCCTA ENSG00000026508 B0081 anti-human CD14 M5E2 TCTCAGACCTCCGTA ENSG00000170458 B0083 anti-human CD16 3G8 AAGTTCACTCTTTGC ENSG00000203747 B0085 anti-human CD25 BC96 TTTGTCCTGTACGCC ENSG00000134460 B0087 anti-human CD45RO UCHL1 CTCCGAATCATGTTG ENSG00000081237 B0088 anti-human CD279 (PD-1) EH12.2H7 ACAGCGCCGTATTTA ENSG00000188389 B0089 anti-human TIGIT (VSTM3) A15153G TTGCTTACCGCCAGA ENSG00000181847 B0090 Mouse IgG1, κ isotype MOPC-21 GCCGGACGACATTAA B0091 Mouse IgG2a, κ isotype MOPC-173 CTCCTACCTAAACTG B0092 Mouse IgG2b, κ isotype MPC-11 ATATGTATCACGCGA B0095 Rat IgG2b, κ isotype RTK4530 GATTCTTGACGACCT B0100 anti-human CD20 2H7 TTCTGGGTCCCTAGA ENSG00000156738 B0101 anti-human CD335 (NKp46) 9E2 ACAATTTGAACAGCG ENSG00000189430 B0124 anti-human CD31 WM59 ACCTTTATGCCACGG ENSG00000261371 B0127 anti-Human Podoplanin NC-08 GGTTACTCGTTGTGT ENSG00000162493 B0134 anti-human CD146 P1H12 CCTTGGATAACATCA ENSG00000076706 B0136 anti-human IgM MHM-88 TAGCGAGCCCGTATA ENSG00000211899 B0138 anti-human CD5 UCHT2 CATTAACGGGATGCC ENSG00000110448 B0141 anti-human CD195 (CCR5) J418F1 CCAAAGTAAGAGCCA ENSG00000160791 B0142 anti-human CD32 FUN-2 GCTTCCGAATTACCG ENSG00000143226 B0143 anti-human CD196 (CCR6) G034E3 GATCCCTTTGTCACT ENSG00000112486 B0144 anti-human CD185 (CXCR5) J252D4 AATTCAACCGTCGCC ENSG00000160683 B0145 anti-human CD103 (Integrin αE) Ber-ACT8 GACCTCATTGTGAAT ENSG00000083457 B0146 anti-human CD69 FN50 GTCTCTTGGCTTAAA ENSG00000110848 B0147 anti-human CD62L DREG-56 GTCCCTGCAACTTGA ENSG00000188404 B0149 anti-human CD161 HP-3G10 GTACGCAGTCCTTCT ENSG00000111796 B0151 anti-human CD152 (CTLA-4) BNI3 ATGGTTCACGTAATC ENSG00000163599 B0152 anti-human CD223 (LAG-3) 11C3C65 CATTTGTCTGCCGGT ENSG00000089692 B0153 anti-human KLRG1 (MAFA) SA231A2 CTTATTTCCTGCCCT ENSG00000139187 B0154 anti-human CD27 O323 GCACTCCTGCATGTA ENSG00000139193 B0155 anti-human CD107a (LAMP-1) H4A3 CAGCCCACTGCAATA ENSG00000185896 B0156 anti-human CD95 (Fas) DX2 CCAGCTCATTAGAGC ENSG00000026103 B0158 anti-human CD134 (OX40) Ber-ACT35 (ACT35) AACCCACCGTTGTTA ENSG00000186827 B0159 anti-human HLA-DR L243 AATAGCGAGCAAGTA ENSG00000204287 B0160 anti-human CD1c L161 GAGCTACTTCACTCG ENSG00000158481 B0161 anti-human CD11b ICRF44 GACAAGTGATCTGCA ENSG00000169896 B0162 anti-human CD64 10.1 AAGTATGCCCTACGA ENSG00000150337 B0163 anti-human CD141 (Thrombomodulin) M80 GGATAACCGCGCTTT ENSG00000178726 B0164 anti-human CD1d 51.1 TCGAGTCGCTTATCA ENSG00000158473 B0165 anti-human CD314 (NKG2D) 1D11 CGTGTTTGTTCCTCA ENSG00000213809 B0167 anti-human CD35 E11 ACTTCCGTCGATCTT ENSG00000203710 B0168 anti-human CD57 Recombinant QA17A04 AACTCCCTATGGAGG ENSG00000109956 B0170 anti-human CD272 (BTLA) MIH26 GTTATTGGACTAAGG ENSG00000186265 B0171 anti-human/mouse/rat CD278 (ICOS) C398.4A CGCGCACCCATTAAA ENSG00000163600 B0174 anti-human CD58 (LFA-3) TS2/9 GTTCCTATGGACGAC ENSG00000116815 B0176 anti-human CD39 A1 TTACCTGGTATCCGT ENSG00000138185 B0179 anti-human CX3CR1 K0124E1 AGTATCGTCTCTGGG ENSG00000168329 B0180 anti-human CD24 ML5 AGATTCCTTCGTGTT ENSG00000272398 B0181 anti-human CD21 Bu32 AACCTAGTAGTTCGG ENSG00000117322 B0185 anti-human CD11a TS2/4 TATATCCTTGTGAGC ENSG00000005844 B0187 anti-human CD79b (Igβ) CB3-1 ATTCTTCAACCGAAG ENSG00000007312 B0189 anti-human CD244 (2B4) C1.7 TCGCTTGGATGGTAG ENSG00000122223 B0206 anti-human CD169 7-239 TACTCAGCGTGTTTG ENSG00000088827 B0214 anti-human/mouse integrin β7 FIB504 TCCTTGGATGTACCG ENSG00000139626 B0215 anti-human CD268 (BAFF-R) 11C1 CGAAGTCGATCCGTA ENSG00000159958 B0216 anti-human CD42b HIP1 TCCTAGTACCGAAGT ENSG00000203618 B0217 anti-human CD54 HA58 CTGATAGACTTGAGT ENSG00000090339 B0218 anti-human CD62P (P-Selectin) AK4 CCTTCCGTATCCCTT ENSG00000174175 B0219 anti-human CD119 (IFN-γ R α chain) GIR-208 TGTGTATTCCCTTGT ENSG00000027697 B0224 anti-human TCR α/β IP26 CGTAACGTAGAGCGA B0236 Rat IgG1, κ isotype RTK2071 ATCAGATGCCCTCAT B0238 Rat IgG2a, κ Isotype RTK2758 AAGTCAGGTTCGTTT B0242 anti-human CD192 (CCR2) K036C2 GAGTTCCCTTACCTG ENSG00000121807 B0246 anti-human CD122 (IL-2Rβ) TU27 TCATTTCCTCCGATT ENSG00000100385 B0352 anti-human FcεRIα AER-37 (CRA-1) CTCGTTTCCGTATCG ENSG00000179639 B0353 anti-human CD41 HIP8 ACGTTGTGGCCTTGT ENSG00000005961 B0355 anti-human CD137 (4-1BB) 4B4-1 CAGTAAGTTCGGGAC ENSG00000049249 B0358 anti-human CD163 GHI/61 GCTTCTCCTTCCTTA ENSG00000177575 B0359 anti-human CD83 HB15e CCACTCATTTCCGGT ENSG00000112149 B0363 anti-human CD124 (IL-4Rα) G077F6 CCGTCCTGATAGATG ENSG00000077238 B0364 anti-human CD13 WM15 TTTCAACGCCCTTTC ENSG00000166825 B0367 anti-human CD2 TS1/8 TACGATTTGTCAGGG ENSG00000116824 B0368 anti-human CD226 (DNAM-1) 11A8 TCTCAGTGTTTGTGG ENSG00000150637 B0369 anti-human CD29 TS2/16 GTATTCCCTCAGTCA ENSG00000150093 B0370 anti-human CD303 (BDCA-2) 201A GAGATGTCCGAATTT ENSG00000198178 B0371 anti-human CD49b P1E6-C5 GCTTTCTTCAGTATG ENSG00000164171 B0373 anti-human CD81 (TAPA-1) 5A6 GTATCCTTCCTTGGC ENSG00000110651 B0384 anti-human IgD IA6-2 CAGTCTCCGTAGAGT ENSG00000211898 B0385 anti-human CD18 TS1/18 TATTGGGACACTTCT ENSG00000160255 B0386 anti-human CD28 CD28.2 TGAGAACGACCCTAA ENSG00000178562 B0389 anti-human CD38 HIT2 TGTACCCGCTTGTGA ENSG00000004468 B0390 anti-human CD127 (IL-7Rα) A019D5 GTGTGTTGTCCTATG ENSG00000168685 B0391 anti-human CD45 HI30 TGCAATTACCCGGAT ENSG00000081237 B0393 anti-human CD22 S-HCL-1 GGGTTGTTGTCTTTG ENSG00000012124 B0394 anti-human CD71 CY1G4 CCGTGTTCCTCATTA ENSG00000072274 B0396 anti-human CD26 BA5b GGTGGCTAGATAATG ENSG00000197635 B0398 anti-human CD115 (CSF-1R) 9-4D2-1E4 AATCACGGTCCTTGT ENSG00000182578 B0404 anti-human CD63 H5C6 GAGATGTCTGCAACT ENSG00000135404 B0406 anti-human CD304 (Neuropilin-1) 12C2 GGACTAAGTTTCGTT ENSG00000099250 B0407 anti-human CD36 5-271 TTCTTTGCCTTGCCA ENSG00000135218 B0408 anti-human CD172a (SIRPα) 15-414 CGTGTTTAACTTGAG ENSG00000198053 B0419 anti-human CD72 3F3 CAGTCGTGGTAGATA ENSG00000137101 B0420 anti-human CD158 (KIR2DL1/S1/S3/S5) HP-MA4 TATCAACCAACGCTT ENSG00000125498 B0446 anti-human CD93 VIMD2 GCGCTACTTCCTTGA ENSG00000125810 B0575 anti-human CD49a TS2/7 ACTGATGGACTCAGA ENSG00000213949 B0576 anti-human CD49d 9F10 CCATTCAACTTCCGG ENSG00000115232 B0577 anti-human CD73 (Ecto-5'-nucleotidase) AD2 CAGTTCCTCAGTTCG ENSG00000135318 B0579 anti-human CD9 HI9a GAGTCACCAATCTGC ENSG00000010278 B0581 anti-human TCR Vα7.2 3C10 TACGAGCAGTATTCA B0582 anti-human TCR Vδ2 B6 TCAGTCAGATGGTAT B0591 anti-human LOX-1 15C4 ACCCTTTACCGAATA ENSG00000173391 B0592 anti-human CD158b (KIR2DL2/L3, NKAT2) DX27 GACCCGTAGTTTGAT ENSG00000243772 B0599 anti-human CD158e1 (KIR3DL1, NKB1) DX9 GGACGCTTTCCTTGA ENSG00000167633 B0822 anti-human CD142 NY2 CACTGCCGTCGATTA ENSG00000117525 B0830 anti-human CD319 (CRACC) 162.1 AGTATGCCATGTCTT ENSG00000026751 B0864 anti-human CD352 (NTB-A) NT-7 AGTTTCCACTCAGGC ENSG00000162739 B0867 anti-human CD94 DX22 CTTTCCGGTCCTACA ENSG00000134539 B0871 anti-human CD162 KPL-1 ATATGTCAGAGCACC ENSG00000110876 B0896 anti-human CD85j (ILT2) GHI/75 CCTTGTGAGGCTATG ENSG00000104972 B0897 anti-human CD23 EBVCS-5 TCTGTATAACCGTCT ENSG00000104921 B0902 anti-human CD328 (Siglec-7) 6-434 CTTAGCATTTCACTG ENSG00000168995 B0918 anti-human HLA-E 3D12 GAGTCGAGAAATCAT ENSG00000204592 B0920 anti-human CD82 ASL-24 TCCCACTTCCGCTTT ENSG00000085117 B0944 anti-human CD101 (BB27) BB27 CTACTTCCCTGTCAA ENSG00000134256 B1046 anti-human CD88 (C5aR) S5/1 GCCGCATGAGAAACA ENSG00000197405 B1052 anti-human CD224 KF29 CTGATGAGATGTCAG ENSG00000100031

  Dataset EGAD50000000252

• A body map of somatic mutagenesis in morphologically normal human tissues

  This dataset contained raw sequencing fastq data of the article "A body map of somatic mutagenesis in morphologically normal human tissues". We sampled morphologically normal tissue biopsies from 5 donors. We performed low-depth WGS on 1,764 samples, high-depth WGS on 48 samples and WES on 1,772 samples.

  Dataset EGAD00001007859

• Irish Covid19 RNASeq Alignment Data files

  The Dataset contains 446 Covid19 patient's RNASeq Alignment files in BAM format for both genomic and transcriptomic alignment.

  Dataset EGAD00001010099

• The Dutch Microbiome Project Batch 1

  The Dutch Microbiome Project (DMP) data includes shotgun metagenomic sequencing of faecal samples 8,208 Dutch individuals. Paired-end sequencing was performed using Illumina HiSeq 2000 platform. Data is archived in two batches to facilitate easier data access and upload to EGA. Batch 1 of DMP includes 4396 samples.

  Dataset EGAD00001007027

• GCAT| WGS BAM V1

  This dataset include BAM files of 808 samples from GCAT cohort. Technology used HiSeq 4000, read length 150 bp, inner mate distance 300 bp. For each sample the paired -ends are generated in separated files. Each FASTQ is splitted in multiple LANEs and grouped by the Multiplex index.

  Dataset EGAD00001008202

• Irish Covid19 WGS Raw Reads

  Dataset contains 483 Irish origin Individuals with Covid19. paired end sequencing has been performed For WGS and later processed by using sention v 201808.03.

  Dataset EGAD00001010186

• Solve-RD multi-omics data chud-faivre cohort

  The dataset includes short-read whole-genome sequencing (SR-WGS) data, SR-RNAseq data, OGM (Bionano) data, LR-WGS data, Epigenetics (RBSS) data and deep-WES data generated within the project Solve-RD from biosamples submitted by the group chud-faivre. The cohorts consists of 111 individuals recruited as part of Solve-RD cohorts 2-4 and aligns with ERN-ITHACA related disease entities (for a description of the Solve-RD cohorts see www.solve-rd.eu/fact-sheet-solve-rd-cohorts).

  Dataset EGAD00001015811

• BC Cancer, part of the Provincial Health Services Authority, Technology Development Office, Data Access Committee (PHSA TDO DAC)

  Access to data generated by BCCA is made available by completing the data access agreement for review by the data access committee and will be granted to qualified investigators for appropriate use.

  Dac EGAC00000000011

• GCAT| WGS FASTQ V1

  This dataset include FASTQ files of 808 samples from GCAT cohort. Technology used HiSeq 4000, read length 150 bp, inner mate distance 300 bp. For each sample the paired -ends are generated in separated files. Each FASTQ is splitted in multiple LANEs and grouped by the Multiplex index.

  Dataset EGAD00001008201